| HIV进入抑制剂的研究进展 |
| |
| 引用本文： | 张浩圆,吴文言. HIV进入抑制剂的研究进展[J]. 中国生物工程杂志, 2011, 31(5): 113-120 |
| |
| 作者姓名： | 张浩圆 吴文言 |
| |
| 作者单位： | 中山大学生命科学学院 广州 510275 |
| |
| 基金项目： | 国家自然科学基金，广州市科技计划项目 |
| |
| 摘 要： | 随着对HIV进入细胞过程的了解,各种进入抑制剂相继问世,目前主要有三大类:吸附抑制剂、辅助受体抑制剂和融合抑制剂.对其中具有代表性的进入抑制剂研究进展进行了介绍,一些进入抑制剂已经进入到了临床试验阶段,其中融合抑制剂T20在2003年便被FDA批准可同其他ARTs联合用于治疗HIV感染者,CCR5拮抗剂Maraviro...
|
| 关 键 词： | HIV 抑制剂 病毒进入 |
| 收稿时间： | 2010-12-21 |
| 修稿时间： | 2011-02-09 |
Research on HIV Entry Inhibitors |
| |
| ZHANG Hao-yuan,WU Wen-yan. Research on HIV Entry Inhibitors[J]. China Biotechnology, 2011, 31(5): 113-120 |
| |
| Authors: | ZHANG Hao-yuan WU Wen-yan |
| |
| Affiliation: | (College of Life Sciences,Sun Yat-sen University,Guangzhou 510275,China) |
| |
| Abstract: | In recent years, various kinds of HIV entry inhibitors have been invented with the discovery of the HIV entry process. They are divided into three main classes: attachment inhibitors, co-receptor binding inhibitors, and fusion inhibitors. The mechanism of action and structure of several important inhibitors are discussed. Many inhibitors are in advanced clinical trials. Especially, the fusion inhibitor T20 has been approved for the treatment of the HIV infected patients with other antiretroviral therapys,by FDA,in 2003 and the CCR5 inhibitor maraviroc has been approved by FDA, in 2007. |
| |
| Keywords: | HIV Inhibitor Viral entry |
| 本文献已被 CNKI 万方数据 等数据库收录！ |
| 点击此处可从《中国生物工程杂志》浏览原始摘要信息 |
|
点击此处可从《中国生物工程杂志》下载全文 |
|
